VenatoRx Pharmaceuticals named a 2018 Best Places to Work
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20180809005673/en/
(L to R from VenatoRx Pharmaceuticals, Inc.) Heather Hunter, Dr. Glen Coburn, Dr. Dan Pevear, Anne Giannopoulos, Dr. Denis Daigle, Jodie Hamrick, Rob Trout, Dr. Christopher Burns, Dr. Bin Liu and Susan Cusick (Photo: Philadelphia Business Journal)
“Being recognized as one of the ‘Best Places to Work’ is a testament to our incredible team, who work tirelessly every day to discover and develop new medicines to treat the increasing threat of bacterial and viral infections,” said Christopher J. Burns, Ph.D., President and CEO of VenatoRx. “We wouldn’t be where we are today without their unwavering commitment to our mission and vision coupled with the financial support from NIAID, NIH, HHS, CARB-X, DTRA, Wellcome Trust, private investors and venture capital firms including Versant Ventures, Abingworth and Foresite Capital.”
“I have had the honor of being a part of this company since its founding eight years ago, and have enjoyed watching it evolve into a robust R&D machine that has the potential to save lives,” said Anne Giannopoulos, Office Manager at VenatoRx, who is the company’s fourth employee. “Throughout our steady growth, we have maintained a small company feel and have created an environment where each person feels like they are contributing and has an impact on the organization. From day one, VenatoRx has been a fun and exciting place to work and I’m inspired by the tremendous opportunity that lays ahead.”
“A major difference between VenatoRx and other pharmaceutical companies is that all of our investigational molecules have been — and will continue to be — discovered internally,” Burns continued. “We have a strong pipeline of clinical and pre-clinical programs, which we believe have the potential to treat multi-drug resistant bacterial infections and hard-to-treat viral infections. As we ramp up for Phase 3 of our lead clinical candidate and progress other pipeline programs from discovery into development, we are actively hiring to support our aggressive strategic growth plan.”
Founded in 2010, VenatoRx has grown from three founders to over 50 employees who are heavily comprised of entrepreneurial-minded scientists and operators who have had career success in big pharma and start-up environments. Headquartered in Malvern, PA, VenatoRx operates in a 25,000 square foot facility comprised of both laboratory and office space. To date, VenatoRx has invented multiple series of novel anti-infective agents and has filed over 30 patent applications.
About the Best Places to Work
The Philadelphia Business Journal, in partnership with Quantum Workplace, honors companies based on a scoring benchmark which reflects employee response rates as well as employee rankings of work environment, people, personal growth, and professional development. The year 2018 yielded a record number of applications for the Best Places to Work and every company included had to reach a scoring benchmark.
About VenatoRx Pharmaceuticals, Inc.
Led by a world-class team of pharmaceutical veterans, VenatoRx is a private pharmaceutical company that is developing a new wave of anti-infective products to address increasing medical needs. VenatoRx’s lead product, VNRX-5133, is an injectable broad-spectrum beta-lactamase inhibitor (BLI) that directly inhibits all four Ambler classes of beta-lactamases. Early clinical studies of cefepime/VNRX-5133 have been completed and VenatoRx plans to start Phase 3 pivotal trials in the second half of 2018. In addition, VenatoRx has a broad pipeline of preclinical programs, including a broad-spectrum orally bioavailable BLI, a novel class of Penicillin-Binding Protein (PBP) inhibitors that are impervious to beta-lactamase-driven resistance, and novel antiviral agents. For more information, please visit www.venatorx.com.
VenatoRx Pharmaceuticals, Inc.
Heather Hunter, 610-644-8935
Vice President, Communications
Source: VenatoRx Pharmaceuticals, Inc.